Short interest for IDEXX Laboratories gives investors a sense of the degree to which investors are betting on the decline of IDEXX Laboratories's stock. Short interest data is updated every two weeks.

IDEXX Laboratories Stock (NASDAQ:IDXX), Short Interest Report

IDEXX Laboratories

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.

Earnings

News

Health Care

Markets

Trading Ideas

General

IDXX

West Pharmaceutical Services, Inc. (NYSE: WST) reported first-quarter 2024 adjusted earnings per share (ETF:EPS) of $1.56, which beat the Zacks Consensus Estimate by 20.9%. The bottom line, however, was down 21.2% year over year.

West Pharmaceutical Q1 Earnings Beat, HVP Sales Weak

Business,Partnership,Meeting,Concept.,Image,Businessmans,Handshake.,Successful,Businessmen,Handshaking

Equities

Management

ELAN

Elanco Animal Health settles with Ancora, expanding board to 14 members, including Ancora&#39;s nominees Craig Wallace and Kathy Turner. Ancora&#39;s significant stake in Elanco, approximately $250 million, has driven discussions on board restructuring and CEO succession planning.

Investor Activism: Elanco Animal Health Settles with Ancora, Adds New Board Members

Wall Street sign

Analyst Color

Large Cap

Mid Cap

Sector ETFs

Bonds

Broad U.S. Equity ETFs

Specialty ETFs

Price Target

Commodities

Reiteration

Small Cap

Economics

Federal Reserve

Intraday Update

Analyst Ratings

Movers

Tech

ETFs

CTLT

SPDR Dow Jones Industrial Average ETF Trust

Market Vectors ETF Trust Market Vectors Gold Miners

NVDA

PLTR

SNAP

iShares Trust Barclays 20+ Year Treasury Bond Fund

VRTX

XLRE

Select Sector SPDR-Consumer Discretionary

Wall Street ends week on negative note as traders revise down expectations on Fed rate cuts. Strong economic data and Fed officials&#39; comments push stocks into red, reducing rate cut expectations for 2024. Treasury yields and dollar strengthen. Small-caps hit hardest.

Stocks Fall As Traders Dial Back Rate Cut Bets; Dollar, Treasury Yields Rise: What&#39;s Driving Markets Monday?

IDEXX Laboratories Inc

<p>IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) has outperformed the market over the past 5 years by 5.0% on an annualized basis producing an average annual return of 16.57%. Currently, IDEXX Laboratories has a market capitalization of $41.47 billion. </p>
<p><strong>Buying $1000 In IDXX:</strong> If an investor had bought $1000 of IDXX stock 5 years ago, it would be worth <strong>$2,164.47</strong> today based on a price of $499.30 for IDXX at the time of writing.</p>
<h3>IDEXX Laboratories's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714167027_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,200 Today

<p><strong>West Pharmaceutical Services, Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wst#NYSE">WST</a>) reported first-quarter 2024 adjusted earnings per share (ETF:EPS) of $1.56, which beat the Zacks Consensus Estimate by 20.9%. The bottom line, however, was down 21.2% year over year.</p>
<p>The adjustments include expenses related to the amortization of acquisition-related intangible assets.</p>
<p>GAAP EPS for the quarter was $1.55, down 16.2% year over year.</p>
<p>The company&#39;s shares have risen 8.1% in the past year compared with the industry&#39;s growth of 4.9%. The broader S&amp;P 500 Index has increased 25.5% in the same time frame.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/84/65685.jpg?v=1798402361" /><br />
Image Source: Zacks Investment Research</p>
<h3>Revenues in Detail</h3>
<p>West Pharmaceutical registered net sales of $695.4 million in the first quarter, down 3% year over year. The figure, however, beat the Zacks Consensus Estimate by 3.3%.</p>
<p>The company recorded an organic net sales decline of 3% in the reported quarter.</p>
<p>Per management, the top-line decline was driven by Proprietary Products&#39; lower high-value product (HVP) sales and weak Generic product sales. However, higher Contract Manufacturing component sales and continued demand for NovaPure and self-injection device platforms partially offset the decline.</p>
<h3>Segmental Details</h3>
<p>West Pharmaceutical operates under two segments &mdash; Proprietary Products and Contract-Manufactured Products.</p>
<p>Net sales in the Proprietary Products segment were $559.5 million, indicating a decline of 4% year over year as well as on an organic basis. HVP net sales, which accounted for approximately 72% of the segment&#39;s net sales, registered an organic decline of low-single-digit percentage points.</p>
<p>The Pharma market units of the Proprietary Products segment reflected a high-single-digit percentage point organic decline in the first-quarter sales. The Generic market unit registered a double-digit percentage point decline in sales. However, low-single-digit organic sales growth for the Biologics market unit partially offset the decline in the Pharma and Generic market units.</p>
<p>Product-wise, the company witnessed continued growth for its NovaPure and self-injection device platforms, along with higher sales for Daikyo Crystal Zenith components, which were more than offset by declines in FluroTec, Westar and standard components.</p>
<p>Net sales in the Contract-Manufactured Products segment increased 1.8% year over year to $135.9 million. Currency translation was a tailwind, boosting sales growth by 50 basis points. The segment saw a 1.3% improvement in organic net sales.</p>
<h3>Margins</h3>
<p>In the quarter under review, West Pharmaceutical&#39;s gross profit decreased 15.1% to $230.2 million. The gross margin contracted nearly 480 basis points (bps) to 33.1%.</p>
<p>Selling, general and administrative expenses rose 0.8% to $86.7 million. Research and development expenses went up 2.9% year over year to $17.6 million.</p>
<p>Adjusted operating profit totaled $123 million, indicating a decrease of 25.4% from the prior-year quarter&#39;s level. The adjusted operating margin contracted 530 bps to 17.7%.</p>
<h3>Financial Position</h3>
<p>West Pharmaceutical exited first-quarter 2024 with cash and cash equivalents of $601.8 million compared with $853.9 million at the end of the fourth quarter. Total debt at the end of the reported quarter was $206.2 million compared with $206.8 million at the end of the previous quarter.</p>
<p>Cumulative net cash flow from operating activities totaled $118.2 million compared with $138.1 million in the year-ago period.</p>
<h3>2024 Guidance</h3>
<p>WST raised its 2024 outlook for earnings but maintained the same for revenues.</p>
<p>It projects adjusted EPS in the range of $7.63-$7.88 for full-year 2024, compared with the previous guidance of $7.50-$7.75. The Zacks Consensus Estimate for the same is pegged at $7.62.</p>
<p>Net sales are projected between $3 billion and $3.025 billion. The Zacks Consensus Estimate for the same is pegged at $3.01 billion. The company expects currency translation to have a positive impact of $8 million on revenues. The organic sales growth estimate is 2-3%.</p>
<h3>Our Take</h3>
<p>West Pharmaceutical exited the first quarter of 2024 with better-than-expected results. The recovery in organic growth is encouraging. However, lower COVID-related sales continue to hurt the top line. The company&#39;s lower-than-market revenue outlook reflects the same. Moreover, contractions in the operating margin do not bode well.</p>
<p>On a positive note, demand for West Pharmaceutical&#39;s HVP products continued to be strong. Robust organic net sales growth in the Pharma, Biologics and Generic market units, excluding COVID-related sales, is another quarterly highlight.</p>
<div class="chart_embed">
<h3>West Pharmaceutical Services, Inc. Price, Consensus and EPS Surprise</h3>
<p><a href="https://www.zacks.com/stock/chart/WST/price-consensus-eps-surprise-chart?icid=chart-WST-price-consensus-eps-surprise-chart"><img alt="West Pharmaceutical Services, Inc. Price, Consensus and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/58/1714051965.png" style="height:265px; width:581px" title="" /> </a></p>
<p>West Pharmaceutical Services, Inc. price-consensus-eps-surprise-chart | West Pharmaceutical Services, Inc. Quote</p>
</div>
<h3>Zacks Rank and Stocks to Consider</h3>
<p>Currently, West Pharmaceutical carries a Zacks Rank #3 (Hold).</p>
<p>Some better-ranked stocks in the broader medical space are <strong>IDEXX Laboratories, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/idxx#NASDAQ">IDXX</a>), <strong>Becton, Dickinson and Company</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bdx#NYSE">BDX</a>), popularly known as BD, and <strong>Ecolab Inc. </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ecl#NYSE">ECL</a>).</p>
<p>IDEXX, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 11.6%. IDXX&#39;s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.3%.&nbsp;</p>
<p>IDEXX&#39;s shares have risen 2.9% compared with the industry&#39;s 3.9% growth in the past year.</p>
<p>BD, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 9.4%. BDX&#39;s earnings surpassed estimates in three of the trailing four quarters and met once, delivering an average surprise of 4.6%.</p>
<p>BD&#39;s shares have lost 11.1% against the industry&#39;s 4.9% growth in the past year.</p>
<p>Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. ECL&#39;s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 1.7%.</p>
<p>Ecolab&#39;s shares have rallied 33.8% against the industry&#39;s 9.3% decline in the past year.</p>
<p><a href="https://www.zacks.com/stock/news/2262524/west-pharmaceutical-wst-q1-earnings-beat-hvp-sales-weak?cid=CS-BENZ-FT-analyst_blog|earnings_article-2262524">To read this article on Zacks.com click here.</a></p>


<p>IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) has outperformed the market over the past 10 years by 13.2% on an annualized basis producing an average annual return of 23.57%. Currently, IDEXX Laboratories has a market capitalization of $40.86 billion. </p>
<p><strong>Buying $1000 In IDXX:</strong> If an investor had bought $1000 of IDXX stock 10 years ago, it would be worth <strong>$8,332.54</strong> today based on a price of $492.00 for IDXX at the time of writing.</p>
<h3>IDEXX Laboratories's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713294032_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$1000 Invested In IDEXX Laboratories 10 Years Ago Would Be Worth This Much Today

<p><strong>Elanco Animal Health Inc</strong>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) has reached a settlement with Ancora, enabling it to sidestep a potential proxy fight with the activist investor, expanding the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/n38018168/elanco-appoints-two-animal-health-industry-executives-kathy-turner-and-craig-wallace-to-its-board-" rel="noreferrer noopener">board to 14 members</a>.</p>
<p>Ancora&#8217;s nominees, Craig Wallace and Kathy Turner, are on its board while retaining its Chief Executive Officer, Jeff Simmons.&nbsp;</p>
<p>Ancora owns approximately 3% of the outstanding common stock of Elanco Animal Health.</p>
<p>The settlement marks a significant development in Elanco&#8217;s corporate governance as it navigates through investor activism. Ancora, with a substantial stake in Elanco amounting to approximately $250 million, had been advocating for various changes within the company, including restructuring its board and succession planning.</p>
<p><strong><em>Related:&nbsp;</em></strong><a target="_blank" href="https://www.benzinga.com/news/earnings/24/02/37314529/elanco-animal-health-reports-mixed-bag-of-q4-earnings-topline-growth-on-price-increase-demand-for-f" rel="noreferrer noopener"><em>This Pet Health Company Sees Growing Demand For Farm-Animal Products, Cost Savings From Restructuring</em></a>.</p>
<p>In February,&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/02/b37390999/ancora-nominates-four-highly-qualified-independent-director-candidates-and-urges-orderly-ceo-succe" rel="noreferrer noopener">Ancora said</a>, &#8220;Based on extensive analysis and good faith engagement with Elanco, it appears that the biggest barriers to success are the company&#8217;s insular Board and unaccountable CEO. It is important to stress that we provided Elanco with a detailed analysis of its issues pertaining to corporate governance, finance, operations, and product development while also privately proposing a settlement framework that accounted for a shareholder-driven refreshment of the board and an orderly succession process in 2025 for long-serving CEO Jeff Simmons.&#8221;</p>
<p>Shares in Elanco have witnessed a notable surge since the beginning of the year, underlining investor optimism regarding the company&#8217;s trajectory. With a current market value of $8 billion, Elanco appears poised to leverage this momentum to address the concerns raised by Ancora and bolster its position in the market, <a href="https://www.bloomberg.com/news/articles/2024-04-01/activist-ancora-is-said-to-win-two-board-seats-at-elanco?sref=TBDibEcD" target="_blank" rel="noreferrer noopener">Bloomberg </a>noted.</p>
<p>Craig Wallace, former CEO (North America/Pacific) of animal health company Ceva Santé Animale, and Kathy Turner, previously the global chief marketing officer at<strong>&nbsp;IDEXX Laboratories Inc</strong>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>), are set to join Elanco&#8217;s board as part of the settlement.&nbsp;</p>
<p>Elanco&#8217;s proactive approach to resolving its differences with Ancora underscores the company&#8217;s dedication to fostering constructive shareholder engagement while maintaining its strategic direction and leadership continuity, the Bloomberg report added.</p>
<p><strong>Price Action: </strong>ELAN shares closed at $16.28 on Thursday.</p>
<p><em>Image sourced from Shutterstock</em></p>


<p>IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) has outperformed the market over the past 20 years by 3.81% on an annualized basis producing an average annual return of 11.64%. Currently, IDEXX Laboratories has a market capitalization of $44.59 billion. </p>
<p><strong>Buying $100 In IDXX:</strong> If an investor had bought $100 of IDXX stock 20 years ago, it would be worth <strong>$901.28</strong> today based on a price of $536.71 for IDXX at the time of writing.</p>
<h3>IDEXX Laboratories's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1711564222_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much You Would Have Made Owning IDEXX Laboratories Stock In The Last 20 Years

<p>IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) has outperformed the market over the past 5 years by 7.8% on an annualized basis producing an average annual return of 20.48%. Currently, IDEXX Laboratories has a market capitalization of $46.65 billion. </p>
<p><strong>Buying $100 In IDXX:</strong> If an investor had bought $100 of IDXX stock 5 years ago, it would be worth <strong>$260.30</strong> today based on a price of $561.41 for IDXX at the time of writing.</p>
<h3>IDEXX Laboratories's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1710176421_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$100 Invested In IDEXX Laboratories 5 Years Ago Would Be Worth This Much Today

<p>IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) has outperformed the market over the past 15 years by 13.65% on an annualized basis producing an average annual return of 27.57%. Currently, IDEXX Laboratories has a market capitalization of $47.73 billion. </p>
<p><strong>Buying $1000 In IDXX:</strong> If an investor had bought $1000 of IDXX stock 15 years ago, it would be worth <strong>$39,996.52</strong> today based on a price of $574.40 for IDXX at the time of writing.</p>
<h3>IDEXX Laboratories's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1709064027_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much $1000 Invested In IDEXX Laboratories 15 Years Ago Would Be Worth Today

<p><strong>IDEXX Laboratories's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NYSE">IDXX</a>) short percent of float has risen 5.93% since its last report. The company recently reported that it has <strong>1.85 million shares sold short</strong>, which is 2.5% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 3.93 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>IDEXX Laboratories Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1708356615_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for IDEXX Laboratories has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing IDEXX Laboratories's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, IDEXX Laboratories's peer group average for short interest as a percentage of float is 3.86%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Peering Into IDEXX Laboratories's Recent Short Interest

<p>IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) has outperformed the market over the past 15 years by 13.63% on an annualized basis producing an average annual return of 26.35%. Currently, IDEXX Laboratories has a market capitalization of $47.64 billion. </p>
<p><strong>Buying $100 In IDXX:</strong> If an investor had bought $100 of IDXX stock 15 years ago, it would be worth <strong>$3,316.62</strong> today based on a price of $573.61 for IDXX at the time of writing.</p>
<h3>IDEXX Laboratories's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1707427826_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much You Would Have Made Owning IDEXX Laboratories Stock In The Last 15 Years

<p>4 analysts have shared their evaluations of IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $615.0, along with a high estimate of $655.00 and a low estimate of $525.00. Surpassing the previous average price target of $568.33, the current average has increased by 8.21%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1707246049_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>A clear picture of IDEXX Laboratories's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$630.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$655.00</td>
<td>$605.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Neutral</td>
<td>$525.00</td>
<td>-</td>
</tr>
<tr>
<td>Nathan Rich</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$650.00</td>
<td>$500.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to IDEXX Laboratories. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of IDEXX Laboratories compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of IDEXX Laboratories's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of IDEXX Laboratories's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/IDXX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on IDEXX Laboratories analyst ratings.</strong></a></p>
<h2>Discovering IDEXX Laboratories: A Closer Look</h2>
<p>Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 40% of its revenue from outside the United States.</p>
<h3>IDEXX Laboratories: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, IDEXX Laboratories showcased positive performance, achieving a revenue growth rate of <strong>8.78%</strong> as of 30 September, 2023. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> IDEXX Laboratories's net margin excels beyond industry benchmarks, reaching <strong>23.18%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>17.75%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> IDEXX Laboratories's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>7.13%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>0.88</strong>, IDEXX Laboratories faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Where IDEXX Laboratories Stands With Analysts

<p>JP Morgan  analyst Chris Schott   maintains IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) with a Overweight and raises the price target from $600 to $630.</p>


JP Morgan Maintains Overweight on IDEXX Laboratories, Raises Price Target to $630

<p>Barclays  analyst Balaji Prasad   maintains IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) with a Overweight and raises the price target from $605 to $655.</p>


Barclays Maintains Overweight on IDEXX Laboratories, Raises Price Target to $655

<p>After enjoying 13 out of 14 positive weeks, Wall Street kicked off Monday on a weaker note as traders revise down their expectations <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/02/36936620/feds-kashkari-echoes-powells-hawkish-stance-monetary-policy-is-not-as-tight-as-we-w">regarding Fed interest rate cuts.</a></p>
<p>Stronger-than-expected economic data — and comments from Federal Reserve officials indicating the central bank has no immediate plans to reduce rates — pushed major U.S. stock averages into the red.</p>
<p>Both Fed Chair <strong>Jerome Powell</strong> and Minneapolis Fed President <strong>Neel Kashkari </strong>issued warnings that monetary policy may remain restrictive for a while due to the remarkable economic resilience.</p>
<p>In January, the services sector expanded beyond expectations, as indicated by the latest ISM PMI figures, marking the strongest growth since September 2023 and extending its 13th <a href="https://www.benzinga.com/news/econ-s/24/02/36934961/us-service-sector-expands-beyond-expectations-in-january-signals-robust-economic-resilience">consecutive month of expansion.</a></p>
<p>Traders have now embraced the idea that a rate cut in March is off the table. Furthermore, they are reducing their rate cut expectations for 2024, going from six rate cuts last week to just about five as of Monday.</p>
<p>Treasury yields surged across all maturity levels, with the 10-year yield increasing by 13 basis points to 4.15%, causing the dollar to strengthen by 0.5% against a basket of major currencies.</p>
<p>Small-cap stocks were hit the hardest, with the <strong>iShares Russell 2000 ETF</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) experiencing a 1.2% decline. Large-cap indices also saw declines, although with a more modest impact.</p>
<p>Bonds fell, with the <strong>iShares 20+ Year Treasury Bond ETF</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) sliding 1.9% after a 2% decline on Friday.</p>
<p>Oil prices rebounded, with West Texas Intermediate (WTI) crude oil rising by 1%, driven by escalating tensions in the Middle East, triggered by U.S. strikes over the weekend that targeted Iran-related sites in Syria and Iraq.</p>
<h2 class="wp-block-heading">Monday&#8217;s Performance In Major Indices, ETFs</h2>
<p><figure class="wp-block-table is-style-stripes"><br />
<table>
<thead>
<tr>
<th>Major Indices &amp; ETFs</th>
<th>Price</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nasdaq 100</td>
<td>17,619.42</td>
<td>-0.1%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>4,947.28</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>38,389.00</td>
<td>-0.7%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,940.18</td>
<td>-1.1%</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p>The <strong>SPDR S&amp;P 500 ETF Trust</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was 0.2% lower to $493.17, the <strong>SPDR Dow Jones Industrial Average</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) fell 0.7% to $383.95 and the tech-heavy <strong>Invesco QQQ Trust</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) eased 0.1% to $428.55, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>. </p>
<p>Sector-wise, the <strong>Technology</strong> <strong>SPDR Select Sector Fund</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, up 0.3%, followed by the <strong>Energy SPDR Select Sector Fund</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>), up 0.1%.  </p>
<p>Notable laggards were the <strong>Real Estate</strong> <strong>SPDR Select Sector Fund</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>), which plummeted 1.8%, and the <strong>Materials</strong> <strong>SPDR Select Sector Fund</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>), down 2.2% </p>
<p>On the industry front, semiconductors rallied, with the<strong> VanEck Semiconductor ETF</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NYSE">SMH</a>) up 1.9%.  </p>
<h2 class="wp-block-heading">Monday&#8217;s Stock Movers</h2>
<ul>
<li><strong>Nvidia Corp.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) rose 4% following a bullish note by Goldman Sachs, which raised <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/02/36933548/nvidia-stock-on-path-to-800-goldman-sachs-says-industry-gold-standard-for-the-futur">its price target on the chipmaker $800. </a></li>
<li><strong>Meta Platforms Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) fell 3% after surging as much as 20% on Friday. </li>
<li><strong>Snap Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NASDAQ">SNAP</a>) fell 4% after the company announced it would cut its workforce by 10%. </li>
<li><strong>Catalent Inc. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTLT#NYSE">CTLT</a>) rose nearly 10% after Danish pharma giant <strong>Novo Nordisk A/S</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) agreed to buy the company for $16.5 billion in cash. </li>
<li><strong>Caterpillar Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) rose nearly 2% after reporting better-than-expected results last quarter. </li>
<li>Other companies reacting to earnings reports were <strong>McDonald&#8217;s Corp. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>), down 4%, <strong>Estee Lauder Companies Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>), up 13%, <strong>Air Products &amp; Chemicals Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>), down 14%, ON <strong>Semiconductor Corp.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>), up 10%, and <strong>IDEXX Laboratories Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>), up 6.4%. </li>
<li>Companies that will report their earnings after the closing bell are <strong>Vertex Pharmaceuticals Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), <strong>Simon Property Group Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPG#NYSE">SPG</a>) and <strong>Palantir Technologies Inc. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)  </li>
</ul>
<p><em>Photo via Shutterstock. </em></p>


Stocks Fall As Traders Dial Back Rate Cut Bets; Dollar, Treasury Yields Rise: What's Driving Markets Monday?

<p><strong>IDEXX Laboratories Inc</strong>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) shares are trading higher after the company released better-than-expected&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/02/b36929120/idexx-announces-fourth-quarter-and-full-year-results" rel="noreferrer noopener">fourth-quarter 2023 financial results</a>.</p>
<p>Animal diagnostic company reported adjusted EPS of $2.32, beating the consensus of $2.12.</p>
<p>The company reported sales of $901.60 million, beating the consensus of $891.25 million.</p>
<p>The sales increased 9% compared to the prior year period on a reported basis and 8% on an organic basis, driven by Companion Animal Group (CAG) growth of 10% reported and 9% organic.</p>
<p>CAG Diagnostics recurring revenue gains of 11% reported and 10% organic in the quarter were supported by continued benefits from IDEXX execution drivers, including placements of CAG Diagnostics capital instruments across regions, high customer retention, new business gains, and net price realization.</p>
<p><strong>Guidance:&nbsp;</strong>IDEXX forecasts fiscal year 2024 sales of $3.93 billion-$4.04 billion versus the consensus of $3.97 billion, reflecting full-year growth of 7.5%-10.5% as reported and 7%-10% on an organic basis.</p>
<p>The company sees a full-year 2024 profit between $10.84 and $11.33 per share versus the consensus of $11.</p>
<p><strong>William Blair&nbsp;</strong>writes that despite a decline in veterinary visits during the quarter, the results from IDEXX highlight the resilience of the global animal health market and the strength of the IDEXX business franchise.&nbsp;</p>
<p>Although negative trends in end-market volume persist, the long-term outlook appears promising due to the increased pet ownership during the pandemic, particularly the puppy boom.&nbsp;</p>
<p>Anticipating a growing demand for veterinary care from an aging pet population starting as early as summer 2024 through 2030, the industry has a positive trajectory.</p>
<p>Supported by pricing growth in the preceding year and the upcoming launch of a novel instrument platform (InVue Dx) in late 2024, the outlook for 2025 remains strong.&nbsp;</p>
<p>Additionally, the veterinary healthcare market is considered a relatively safe investment.&nbsp;</p>
<p>The analysts reiterated the stock&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/IDXX/analyst-ratings" rel="noreferrer noopener">with an Outperform rating</a>.</p>
<p><strong>Price Action:</strong> IDXX shares are up 6.1% at $559.32 on the last check Monday.</p>
<p><em>Photo by <a href="https://commons.wikimedia.org/w/index.php?curid=92754000">Wikimedia Commons</a></em></p>


Guidance

Why Is Animal Diagnostic-Focused IDEXX Laboratories Stock Trading Higher Today?

<p>Deep-pocketed investors have adopted a bullish approach towards IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in IDXX usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 14 extraordinary options activities for IDEXX Laboratories. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 71% leaning bullish and 28% bearish. Among these notable options, 3 are puts, totaling $195,980, and 11 are calls, amounting to $548,686.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $290.0 to $580.0 for IDEXX Laboratories over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for IDEXX Laboratories's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of IDEXX Laboratories's whale activity within a strike price range from $290.0 to $580.0 in the last 30 days. </p>
<h3>IDEXX Laboratories Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1707155150_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>IDXX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/16/24</td>
<td>$530.00</td>
<td>$171.2K</td>
<td style="text-align: right;">90</td>
<td style="text-align: right;">82</td>
</tr>
<tr>
<td>IDXX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$560.00</td>
<td>$76.3K</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">14</td>
</tr>
<tr>
<td>IDXX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$560.00</td>
<td>$70.7K</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">27</td>
</tr>
<tr>
<td>IDXX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$580.00</td>
<td>$65.6K</td>
<td style="text-align: right;">43</td>
<td style="text-align: right;">34</td>
</tr>
<tr>
<td>IDXX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$540.00</td>
<td>$56.1K</td>
<td style="text-align: right;">15</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
</p>
<h3>About IDEXX Laboratories</h3>
<p>Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 40% of its revenue from outside the United States.</p>
<p>Following our analysis of the options activities associated with IDEXX Laboratories, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of IDEXX Laboratories</h3>
<ul>
<li>With a volume of 447,358, the price of IDXX is up 0.54% at $530.0. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 0 days.</li>
</ul>
<h3>Professional Analyst Ratings for IDEXX Laboratories</h3>
<p>A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $587.5.</p>
<ul>
<li>An analyst from Piper Sandler has revised its rating downward to Neutral, adjusting the price target to $525. </li>
<li>Maintaining their stance, an analyst from Goldman Sachs continues to hold a Buy rating for IDEXX Laboratories, targeting a price of $650. </li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for IDEXX Laboratories with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

A Closer Look at IDEXX Laboratories's Options Market Dynamics

WIIM

IDEXX Laboratories shares are trading higher after the company reported better-than-expected Q4 results.

IDEXX Laboratories Forecasts FY24 EPS Of $10.84-$11.33 Versus Consensus Of $11.00, Reflecting Reported And Organic Growth Of 8%-13%

IDEXX Laboratories Forecasts FY24 Sales Of $3.93B-$4.04B Versus Consensus Of $3.97B, Reflecting Full Year Growth Of 7.5%-10.5% As Reported And 7%-10% On An Organic Basis

<p>IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) reported quarterly earnings of $2.34 per share which beat the analyst consensus estimate of $2.12 by 10.38 percent. This is a 17 percent increase over earnings of $2.00 per share from the same period last year.  The company reported quarterly sales of $901.60 million which beat the analyst consensus estimate of $891.25 million by 1.16 percent.  This is a 8.81 percent increase over sales of $828.57 million the same period last year.</p>


IDEXX Laboratories Q4 Adjusted PS $2.34 Beats $2.12 Estimate, Sales $901.60M Beat $891.25M Estimate

<h3>Companies Reporting Before The Bell</h3>
<p>&bull; NAPCO Security Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSSC#NASDAQ">NSSC</a>) is estimated to report quarterly earnings at $0.26 per share on revenue of $43.92 million.</p>
<p>&bull; Affiliated Managers Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMG#NYSE">AMG</a>) is projected to report quarterly earnings at $5.98 per share on revenue of $524.15 million.</p>
<p>&bull; Sphere Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPHR#NYSE">SPHR</a>) is expected to report quarterly loss at $0.85 per share on revenue of $300.23 million.</p>
<p>&bull; Bowlero (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOWL#NYSE">BOWL</a>) is estimated to report quarterly earnings at $0.12 per share on revenue of $300.52 million.</p>
<p>&bull; ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) is estimated to report quarterly earnings at $1.21 per share on revenue of $2.00 billion.</p>
<p>&bull; Tyson Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) is likely to report quarterly earnings at $0.40 per share on revenue of $13.36 billion.</p>
<p>&bull; McDonald&#39;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) is likely to report quarterly earnings at $2.82 per share on revenue of $6.45 billion.</p>
<p>&bull; Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) is expected to report quarterly earnings at $0.55 per share on revenue of $4.20 billion.</p>
<p>&bull; IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) is expected to report quarterly earnings at $2.11 per share on revenue of $889.85 million.</p>
<p>&bull; Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) is projected to report quarterly earnings at $4.75 per share on revenue of $17.11 billion.</p>
<p>&bull; Graham (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHM#NYSE">GHM</a>) is projected to report quarterly loss at $0.03 per share on revenue of $38.94 million.</p>
<p>&bull; CNA Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNA#NYSE">CNA</a>) is likely to report quarterly earnings at $1.10 per share on revenue of $2.95 billion.</p>
<p>&bull; Mitsubishi UFJ Finl Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUFG#NYSE">MUFG</a>) is projected to report earnings for its third quarter.</p>
<p>&bull; Timken (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKR#NYSE">TKR</a>) is estimated to report quarterly earnings at $1.22 per share on revenue of $1.06 billion.</p>
<p>&bull; Loews (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/L#NYSE">L</a>) is likely to report earnings for its fourth quarter.</p>
<p>&bull; Mesa Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLAB#NASDAQ">MLAB</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $54.89 million.</p>
<p>&bull; Air Products &amp; Chemicals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>) is expected to report quarterly earnings at $3.00 per share on revenue of $3.20 billion.</p>
<h3>Companies Reporting After The Bell</h3>
<p>&bull; Bright Scholar Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEDU#NYSE">BEDU</a>) is projected to report earnings for its first quarter.</p>
<p>&bull; IRSA Inversiones y (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRS#NYSE">IRS</a>) is estimated to report earnings for its second quarter.</p>
<p>&bull; Kilroy Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRC#NYSE">KRC</a>) is projected to report earnings for its fourth quarter.</p>
<p>&bull; BellRing Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRBR#NYSE">BRBR</a>) is estimated to report quarterly earnings at $0.39 per share on revenue of $412.86 million.</p>
<p>&bull; Hillenbrand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HI#NYSE">HI</a>) is expected to report quarterly earnings at $0.68 per share on revenue of $777.81 million.</p>
<p>&bull; NXP Semiconductors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) is estimated to report quarterly earnings at $3.63 per share on revenue of $3.40 billion.</p>
<p>&bull; Symbotic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) is likely to report quarterly loss at $0.06 per share on revenue of $368.89 million.</p>
<p>&bull; Golub Capital BDC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBDC#NASDAQ">GBDC</a>) is likely to report quarterly earnings at $0.48 per share on revenue of $160.51 million.</p>
<p>&bull; Kforce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KFRC#NASDAQ">KFRC</a>) is projected to report quarterly earnings at $0.79 per share on revenue of $363.36 million.</p>
<p>&bull; Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) is estimated to report quarterly earnings at $4.09 per share on revenue of $2.51 billion.</p>
<p>&bull; Itau Unibanco Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITUB#NYSE">ITUB</a>) is estimated to report quarterly earnings at $0.19 per share on revenue of $7.99 billion.</p>
<p>&bull; United States Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) is projected to report quarterly earnings at $0.37 per share on revenue of $299.98 million.</p>
<p>&bull; Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) is expected to report quarterly earnings at $0.07 per share on revenue of $602.55 million.</p>
<p>&bull; Skyline Champion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKY#NYSE">SKY</a>) is estimated to report quarterly earnings at $0.64 per share on revenue of $499.72 million.</p>
<p>&bull; AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) is likely to report quarterly earnings at $0.95 per share on revenue of $3.66 billion.</p>
<p>&bull; Amkor Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) is expected to report quarterly earnings at $0.41 per share on revenue of $1.68 billion.</p>
<p>&bull; Coherent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>) is likely to report quarterly earnings at $0.26 per share on revenue of $1.12 billion.</p>
<p>&bull; Simpson Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSD#NYSE">SSD</a>) is estimated to report quarterly earnings at $1.48 per share on revenue of $482.21 million.</p>
<p>&bull; Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) is projected to report quarterly earnings at $2.03 per share on revenue of $693.15 million.</p>
<p>&bull; Kimball Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KE#NASDAQ">KE</a>) is estimated to report quarterly earnings at $0.44 per share on revenue of $435.67 million.</p>
<p>&bull; Cabot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBT#NYSE">CBT</a>) is likely to report quarterly earnings at $1.49 per share on revenue of $952.85 million.</p>
<p>&bull; ChampionX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHX#NASDAQ">CHX</a>) is likely to report quarterly earnings at $0.44 per share on revenue of $950.17 million.</p>
<p>&bull; Crown Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) is estimated to report quarterly earnings at $1.43 per share on revenue of $2.95 billion.</p>
<p>&bull; Flexsteel Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLXS#NASDAQ">FLXS</a>) is likely to report quarterly earnings at $0.56 per share on revenue of $102.12 million.</p>
<p>&bull; Gladstone Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLAD#NASDAQ">GLAD</a>) is projected to report quarterly earnings at $0.28 per share on revenue of $23.39 million.</p>
<p>&bull; Rambus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NASDAQ">RMBS</a>) is estimated to report quarterly earnings at $0.45 per share on revenue of $134.00 million.</p>
<p>&bull; Chegg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) is estimated to report quarterly earnings at $0.36 per share on revenue of $187.44 million.</p>
<p>&bull; Simon Property Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPG#NYSE">SPG</a>) is estimated to report earnings for its fourth quarter.</p>
<p>&bull; Varonis Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNS#NASDAQ">VRNS</a>) is estimated to report quarterly earnings at $0.23 per share on revenue of $151.88 million.</p>
<p>&bull; Intevac (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVAC#NASDAQ">IVAC</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $9.70 million.</p>
<p>&bull; FMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) is estimated to report quarterly earnings at $1.08 per share on revenue of $1.25 billion.</p>
<p>&bull; J&amp;J Snack Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JJSF#NASDAQ">JJSF</a>) is expected to report quarterly earnings at $0.78 per share on revenue of $362.88 million.</p>
<p>This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.</p>


AMKR

BEDU

BOWL

BRBR

CHGG

COHR

FLXS

GBDC

GLAD

ITUB

IVAC

JJSF

KFRC

MLAB

MUFG

NSSC

NXPI

RMBS

SPHR

VRNS

Earnings Scheduled For February 5, 2024

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Inozyme Pharma (INZY – Research Report), Zai Lab (ZLAB – Research...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Zai Lab (ZLAB) and Idexx Laboratories (IDXX)

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>You may have heard about GPT-4 Turbo, Gemini, Llama or <strong>X&rsquo;s</strong> (formerly Twitter) Grok. However, there is a new contender outside of these Big Tech models in town. It&rsquo;s called Claude, created by <strong>Anthropic</strong>. The company recently <a href="https://www.anthropic.com/news/claude-3-family">released Claude 3 models</a> and claims its premium &ldquo;Opus&rdquo; model is smarter than all other AI bots. Many people have touted it as the most intelligent AI available right now. Moreover, it has access to events up to August 2023, making it more up-to-date than other models.</p>



<p>Could Claude&rsquo;s stock screening capabilities and human intuition help you realize significant returns? Let&rsquo;s put it to the test and ask it to list seven stocks that it thinks will &ldquo;mint millionaires.&rdquo; Note that some highly unprofitable and dilutive companies and big-cap picks unlikely to deliver &ldquo;millionaire-making&rdquo; gains have been left out of the AI stock picks for obvious reasons.</p>



<h2>Paycom Software (PAYC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/PAYC1600-300x169.jpg" alt=""><div>Source: STEFANY LUNA DE LINZY / Shutterstock.com</div></div><p>Claude: &ldquo;<strong>Paycom Software</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/payc-stock-quote/"><strong>PAYC</strong></a></span>) is a leading provider of cloud-based payroll and human resource management software for small to medium-sized businesses. The company&rsquo;s platform offers a range of tools for managing payroll, time and attendance, talent acquisition, and HR compliance. Paycom&rsquo;s user-friendly interface, strong customer support, and focus on innovation have helped it gain a loyal customer base and maintain high retention rates. The increasing demand for cloud-based payroll and HR solutions, driven by the need for businesses to streamline their processes and ensure compliance with evolving regulations, supports Paycom&rsquo;s growth prospects. Additionally, the ongoing shift towards digital transformation and the increasing technology adoption by small and medium-sized businesses are key megatrends that benefit Paycom.&rdquo;</p>



<p>Claude has hit the nail on the head regarding the trends driving long-term growth for Paycom&rsquo;s business. There is not much to add except looking at the metrics. Most cloud-based software companies are trading at significant premiums right now. Still, I cannot say the same for PAYC, trading 63% off its 2021 peak despite generating solid profits and paying a small dividend. However, I believe times will change as companies accelerate efforts to automate their workforce. Analysts expect continued EPS and revenue growth in <a href="https://seekingalpha.com/symbol/PAYC/earnings/estimates">low double-digits</a> going forward, which are relatively muted expectations the company can beat. I agree that outsized returns are definitely possible here from these depressed levels.</p>



<h2>Vicor (VICR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/defense1600d-300x169.jpg" alt="8 Stellar Small-Cap Stocks to Buy That Are in Major Industries"><div>Source: Shutterstock</div></div><p>Claude: &ldquo;<strong>Vicor</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/vicr-stock-quote/"><strong>VICR</strong></a></span>) is a leading high-performance power conversion and management solutions provider. The company&rsquo;s innovative products are used in various industries, including automotive, aerospace, defense and data centers. Vicor&rsquo;s patented technology enables efficient, high-density power delivery, crucial for the growing demand for electrification and high-performance computing. The company&rsquo;s strong market position, expanding customer base and exposure to key megatrends such as electric vehicles and data center growth make it a compelling investment opportunity.&rdquo;</p>



<p>This power modules company is another beaten-down bet that can deliver significant returns. I agree with Claude that the risk-return setup here is favorable for investors. However, I am not as optimistic as AI on the near-term prospects. Analysts expect EPS to recover from $0.32 to $1.26 in one year, along with 33% revenue growth. However, the revenue of $92.7 million in Q4 was down ~12% sequentially and on a YOY basis. The company missed consensus revenue estimates by a whopping $14.4 million while book-to-bill remained below 1. These are concerning metrics for the near term, but I cannot complain much about the long-term prospects with shares at bargain-basement levels.</p>



<h2>Enphase Energy (ENPH)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/07/enph1600-300x169.png" alt="Smartphone with logo of American company company Enphase Energy Inc. (ENPH) on screen in front of business website. Focus on left of phone display. Unmodified photo."><div>Source: T. Schneider / Shutterstock.com</div></div><p>Claude: &ldquo;<strong>Enphase Energy</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/enph-stock-quote/"><strong>ENPH</strong></a>) is a global leader in microinverter-based solar-plus-storage systems. The company&rsquo;s innovative technology enables more efficient and reliable solar energy generation and storage, making it a key player in the growing renewable energy market. Enphase&rsquo;s strong brand, expanding global presence and partnerships with leading solar installers position it well for future growth. The increasing adoption of solar energy, the need for energy storage solutions and the global push towards renewable energy are significant megatrends that support Enphase&rsquo;s long-term prospects.&rdquo;</p>



<p>Speaking of bargain-basement pricing, Enphase Energy certainly has you covered there. The entire solar sector went through a bearish wave in the past few months, but that seems to be subsiding with many <a href="https://investorplace.com/industries/energy/renewable-energy/solar/">solar stocks</a> recovering from their troughs. Enphase has recovered significantly but is still down 64% from its peak. I believe these cheap prices have significant upside potential as rate cuts take effect. The company has $1.7 billion in cash and huge growth ahead, with residential installations only comprising over 20% of the overall capacity installed in the U.S. Analysts expect EPS to rise from $3.3 in 2024 to $11.4 in 2029 alongside revenue growing from $1.6 billion to $4.4 billion during the same period. It&rsquo;s definitely one of the best AI stock picks here.</p>



<h2>Revolve Group (RVLV)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/06/revolve-rvlv-stock-300x169.jpg" alt="The Revolve (RVLV) group logo is seen on a display."><div>Source: nikkimeel / Shutterstock.com</div></div><p>Claude: &ldquo;<strong>Revolve Group</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/rvlv-stock-quote/"><strong>RVLV</strong></a>) is an online fashion retailer that targets Millennial and Gen Z consumers. The company&rsquo;s data-driven approach, influencer-driven marketing and curated product offerings have helped it build a loyal customer base and differentiate itself in the competitive e-commerce market. Revolve&rsquo;s agile supply chain, strong brand partnerships and focus on customer experience position it well for continued growth. The increasing shift towards online shopping, the growing influence of social media on consumer behavior and the rising spending power of younger generations are key megatrends that support Revolve&rsquo;s growth prospects.&rdquo;</p>



<p>This is another beaten-down stock among the AI stock picks that I think can perform relatively well in the years ahead. However, I again would not be very optimistic here in the near term, given retail spending is still down and high interest rates have dampened discretionary purchases. However, I would still say this deserves a buy rating because the balance sheet is quite clean, with only $41 million in debt and $245 million in cash. The growth potential cannot be ignored, as analysts expect EPS to jump from $0.48 to $6.3 from 2024 to 2033 and revenue nearly quadrupling in that timeframe. In the long run, I have a lot of conviction that you can squeeze out significant upside from this stock from the current depressed levels.</p>



<h2>IDEXX Laboratories (IDXX)</h2>



<a href="https://investorplace.com/wp-content/uploads/2016/07/IDEXX-01.png"><img width="280" height="280" src="https://investorplace.com/wp-content/uploads/2016/07/IDEXX-01.png" alt=""></a><p>Claude: &ldquo;<strong>IDEXX Laboratories</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/idxx-stock-quote/"><strong>IDXX</strong></a>) is a global leader in veterinary diagnostics, software and water microbiology testing. The company&rsquo;s innovative products and services help veterinarians deliver high-quality care and enable early detection and treatment of pet diseases. IDEXX&rsquo;s strong competitive position, global presence and innovation focus position it well for continued growth. The increasing humanization of pets, the growing demand for veterinary care and the rising awareness of early disease detection&rsquo;s importance are key megatrends supporting IDEXX&rsquo;s long-term prospects.&rdquo;</p>



<p>You could include this company in your core portfolio without hesitation. Still, I do not think this is the sort of stock you would necessarily chase if you are looking for millionaire-making returns. Regardless, you could still make some juicy gains if you hold this long enough. It is a quality company, but I disagree with Claude that it can generate the multibagger returns I am targeting in the next few years.</p>



<h2>Tactile Systems Technology (TCMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/medical-device-stocks-hospital-stocks-healthcare-stocks-300x169.jpg" alt="An image of two medical professionals performing a procedure on a patient"><div>Source: Roman Zaiets / Shutterstock.com</div></div><p>Claude: &ldquo;<strong>Tactile Systems</strong> <strong>Technology</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/tcmd-stock-quote/"><strong>TCMD</strong></a></span>) is a medical technology company that develops and provides innovative medical devices for treating chronic diseases at home. The company&rsquo;s flagship product, the Flexitouch system, treats lymphedema and chronic venous insufficiency. Tactile Systems&rsquo; focus on improving patient outcomes, reducing healthcare costs and enabling at-home treatment positions it well for future growth. The increasing prevalence of chronic diseases, the growing demand for home-based healthcare solutions and the ongoing shift toward value-based care are key megatrends that support Tactile Systems&rsquo; growth prospects.&rdquo;</p>



<p>This is certainly one of the AI stock picks that could deliver the oversized returns I discussed. <a href="https://seekingalpha.com/symbol/TCMD/earnings/estimates">EPS is expected </a>to double in the next two years nearly, and revenue is growing in the lower double digits. The valuation and margins are very appealing here, and the 3-year FCF growth rate of 281% makes it better than 99.7% of its industry peers. It is a quality company with a clean balance sheet. Still, the potential upside is a bit muted, and I do not expect TCMD stock to break $50 anytime soon.</p>



<h2>Simulations Plus (SLP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/healthcare-1600-300x169.jpg" alt="Nurse holding a tablet with icons representing different aspects of healthcare and healthcare data representing CANO stock. Healthcare Tech Stocks"><div>Source: metamorworks / Shutterstock</div></div><p>Claude: &ldquo;<strong>Simulations Plus</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/slp-stock-quote/"><strong>SLP</strong></a></span>) is a leading modeling and simulation software provider for drug discovery and development. The company&rsquo;s innovative software platform helps pharmaceutical and biotechnology companies accelerate the drug development process, reduce costs and improve success rates. Simulations Plus&rsquo; strong market position, expanding customer base and focus on innovation position are good for continued growth. The increasing complexity of drug discovery, the growing demand for efficient drug development processes and the rising adoption of computer-aided drug design are key megatrends that support Simulations Plus&rsquo; long-term prospects.&rdquo;</p>



<p>This is another stock in the healthcare industry sort of in the same boat as TCMD. Do not expect massive returns, but the possible gains are significant enough to include in a high-risk, high-reward basket of stocks. The company beat top-line estimates by nearly 6% in the recent quarter and has some of the best margin and cash positions, with negligible debt and $108 million in cash. Revenue growth is expected to be around 15% annually and 20-30% EPS growth going forward. However, you are paying a hefty premium for this stock, so I do not think life-changing returns are possible. However, it is still one of the AI stock picks worth buying for potential double-digit returns.</p>



<p><em>On the date of publication, Omor Ibne Ehsan did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines.</a></em></p>
<div><p>Omor Ibne Ehsan is a writer at InvestorPlace. He is a self-taught investor with a focus on growth and cyclical stocks that have strong fundamentals, value, and long-term potential. He also has an interest in high-risk, high-reward investments such as cryptocurrencies and penny stocks. You can follow him on <a href="https://www.linkedin.com/in/omor-ibne-ehsan-56068022b/">LinkedIn</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/04/new-ai-bot-predicts-these-7-stocks-will-mint-millionaires/">New AI Bot Predicts These 7 Stocks Will Mint Millionaires</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

New AI Bot Predicts These 7 Stocks Will Mint Millionaires

Top 10 most oversold S&P 500 stocks

Baron Focused Growth Fund Q1 2024 Shareholder Letter

The spread of avian flu to cattle could have implications for some stocks

With rate cuts pushed out, Goldman looks at quality stocks

The "highest quality" stocks within each sector - GS

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Healthequity (HQY – Research Report), Cellectis SA (...

-

-

-

-

-

-

-

-

-

-

-

-

-

-

IDEXX Laboratories Stock (NASDAQ:IDXX), Short Interest Report

People Also Watch